Tonix Pharmaceuticals has reported positive topline outcomes from its Phase I single ascending dose study of its ...

Company had $98.8 million in cash as of December 31, 2024; existing cash expected to fund planned operations into the first ...

Tonix Pharmaceuticals saw its shares swing wildly between gains and losses on Wednesday morning as they started to trade ...

Clinical-stage biopharmaceutical company Tonix Pharmaceuticals (NASDAQ: TNXP) is gaining significant attention from investors ...

EST Tonix Pharmaceuticals (TNXP) trading halted, news pendingMaximize Your Portfolio with Data Driven Insights:Leverage the power of ...

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced ...

Tonix Pharmaceuticals Holding Corp.’s TNXP share price has dipped by 54.47%, which has investors questioning if this is right ...

Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Tonix ...

Ms. Fogarty has served at Tonix since 2016, most recently as Executive Vice President, Product Development Tonix is Preparing for Potential Launch of TNX-102 SL for the management of fibromyalgia with ...

Company had $98.8 million in cash as of December 31, 2024; existing cash expected to fund planned operations into the first quarter of 2026 Company is debt-free after repaying mortgage on facilities ...